Drug Trial Radar · NCT07904806
Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Dec 15, 2026
Primary completion
Nov 20, 2029
Study completion Nov 20, 2029
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, double-blind, randomized, controlled, multicenter trial evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of 2 VIS954 dosing regimens in patients with moderate to severe acute anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).
Conditions
- Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
VIS954Drug
SC injection
Standard Of Care (SOC)Drug
Glucocorticoids and rituximab or cyclophosphamide will be administered as standard-of-care induction therapy at the investigator's discretion and in accordance with local practice and applicable treatment guidelines.
PlaceboDrug
SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants in Remission at Week 24Time frame: Week 24
- Incidence of Treatment-Emergent Adverse Events (TEAEs) Through Week 24Time frame: Baseline through Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.